GMP-relevant growth factors for regenerative medicine
APPLICATION WORKFLOWS
iPSC, organoid, tissue-differentiation & disease-model workflows.
Why fully-human — Differentiation is dose- and quality-sensitive: aglycosylated, endotoxin-bearing E. coli factors give variable potency and derail lineage commitment.
GMP regenerative protocols need glycosylated, endotoxin-free, lot-consistent factors.
Product candidates
- Activin A
- BMP4/BMP7
- FGF2
- EGF/KGF
- HGF
- VEGF-A
- IGF-1
- NGF/GDNF
- Netrin-1 (NTN1)
STRATEGIC ROLE
A human secretory pathway, not a refolding line
Each factor is expressed in human iPSC-derived cells, so disulfide-rich, dimeric growth factors — Activin A / BMP dimers, the NGF / GDNF cystine-knot, glyco-VEGF — are folded, pro-processed and N-/O-glycosylated by native human machinery.
Endotoxin-free, serum-free and clone-free (no clonal drift); adenovirus-driven expression gives GMP-consistent lots no E. coli refold or CHO clone can reproduce.
Native human cytokines for immune-cell manufacturing
APPLICATION WORKFLOWS
T-cell, NK-cell, macrophage & dendritic-cell expansion, activation & differentiation.
Why fully-human — Cell-therapy potency tracks cytokine glycosylation & stability. E. coli cytokines aggregate, drift in specific activity and carry endotoxin — forcing costly re-validation. Manufacturing needs animal-free, native, drop-in cytokines.
Product candidates
- IL-2
- IL-7
- IL-15
- IL-21
- IL-10/12
- GM-CSF
- SCF
- FLT3L
STRATEGIC ROLE
Glycosylated, native-potency cytokines
Produced in human cells with authentic O-/N-glycosylation — O-glycosylated IL-2 as T-cells secrete it, glyco-GM-CSF / SCF — so they are non-aggregating, endotoxin-free and carry native specific activity & half-life.
Heterodimeric IL-12 (p35 / p40) is correctly assembled by multi-gene adenoviral co-expression, which single-chain E. coli systems cannot do.
Therapeutic proof asset
APPLICATION WORKFLOWS
Native replacement proteins for high-unmet-need indications — OA, COPD, hemorrhage, ARDS, hemolysis, sarcopenia.
Why fully-human — These are large, glycosylated, multimeric plasma proteins. Donor plasma is scarce and biohazardous, and CHO / E. coli miss their glycosylation & higher-order assembly — only authentic human proteoforms are active and safe.
Product candidates
- PRG4 Dry Eye/Osteoarthritis
- A2M Osteoarthritis
- AAT COPD
- Fibrinogen Hemorrhage
- SP-D ARDS
- Hemopexin Hemolysis
- FST315 Sarcopenia
STRATEGIC ROLE
Complex glycosylation & higher-order assembly
Our human-cell hosts rebuild what conventional systems drop: mucin-type O-glycosylation (PRG4), correct Aα / Bβ / γ assembly of fibrinogen, collagen-domain multimerization of SP-D, and properly glycosylated AAT / A2M / hemopexin — via tissue-matched iPSC cells and multi-gene co-expression, yielding active, authentic human proteoforms.
Complex-protein showcase
APPLICATION WORKFLOWS
Hardest-target validation - HDL / lipoproteins, lipidated morphogens, membrane heme enzymes (cardiovascular, organoid, ADME-tox).
Why fully-human — They require lipidation, particle assembly and membrane / heme machinery absent in bacteria and CHO. No vendor offers functional native forms — a human-cell system is the only route.
Product candidates
- rHDL (ApoA-I) Reconstituted HDL — multi-subunit lipoprotein assembly
- Lipidated Wnt (Wnt3a/5a)Palmitoleoylated morphogens — lipid post-translational modification
- CYP enzymes (CYP3A4/2D6)Membrane heme-cofactor enzymes — functional folding & activity
STRATEGIC ROLE
Lipidation, particle & membrane / heme machinery
Only a human-cell system carries the modifying enzymes these proteins need — PORCN palmitoleoylation of Wnt3a / 5a, ApoA-I lipidation into functional HDL particles, and heme insertion with correct membrane topology for CYP3A4 / 2D6.
NSiS co-expresses each protein with its modifying enzymes and chaperones by adenoviral multi-gene delivery.
High-quality whole antigen for antibody library
APPLICATION WORKFLOWS
Whole antigens to drive antibody-library discovery against intractable viral & glyco targets.
Why fully-human — Discovery fails when antigen glycans / epitopes are wrong. Insect / E. coli antigens misdisplay the glycan shield & conformational epitopes — campaigns need authentic human-glycosylated, natively folded whole antigens.
Product candidates
- Lassa virus
- Nipah virus
- HIV-1 Env
- EBV
- HNK-1-bearing glycoproteins
STRATEGIC ROLE
Authentic human glyco-epitopes
Whole, full-length antigens carry native human N-/O-glycosylation — including the HNK-1 (3-sulfoglucuronyl) epitope via the human sulfotransferase repertoire — preserving conformational and glycan-shield epitopes (HIV-1 Env trimer, viral glycoproteins).
Multi-gene co-expression restores native oligomeric state for discovery-grade antigens.